2024
Procedure Volume and Outcomes With WATCHMAN Left Atrial Appendage Occlusion
Friedman D, Du C, Zimmerman S, Tan Z, Lin Z, Vemulapalli S, Kosinski A, Piccini J, Pereira L, Minges K, Faridi K, Masoudi F, Curtis J, Freeman J. Procedure Volume and Outcomes With WATCHMAN Left Atrial Appendage Occlusion. Circulation Cardiovascular Interventions 2024, 17: e013466. PMID: 38889251, PMCID: PMC11189610, DOI: 10.1161/circinterventions.123.013466.Peer-Reviewed Original ResearchConceptsVolume-outcome relationshipLikelihood of procedural successLeft atrial appendage occlusionProcedural successProcedure volumeAppendage occlusionNational Cardiovascular Data Registry LAAO RegistryVolume quartilesLeft atrial appendage occlusion devicesThree-level hierarchical generalized linear modelsMinimum volume thresholdsWatchman FLX deviceProcedural success rateHierarchical generalized linear modelsAssociated with outcomePhysician volumeWATCHMAN procedureFLX deviceOcclusion deviceVolume thresholdCardiovascular proceduresPhysiciansHospitalNational analysisSuccess rate
2020
Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice
Sherwood MW, Piccini JP, Holmes DN, Pieper KS, Steinberg BA, Fonarow GC, Allen LA, Naccarelli GV, Kowey PR, Gersh BJ, Mahaffey KW, Singer DE, Ansell JE, Freeman JV, Chan PS, Reiffel JA, Blanco R, Peterson ED, Rao SV. Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice. Circulation Cardiovascular Interventions 2020, 13: e008274. PMID: 32408815, DOI: 10.1161/circinterventions.119.008274.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAnticoagulantsAtrial FibrillationCardiac CatheterizationDrug Administration ScheduleFactor Xa InhibitorsFemaleHemorrhageHumansMaleMiddle AgedPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsRegistriesRisk AssessmentRisk FactorsStrokeTime FactorsTreatment OutcomeUnited StatesWarfarinConceptsDirect-Acting Oral AnticoagulantsActing Oral AnticoagulantsOral anticoagulationCardiac catheterizationRadial artery accessAtrial fibrillationMajor bleedingOral anticoagulantsMedian ageArtery accessAtrial Fibrillation II registryPatients' median ageReal-world registryChronic kidney diseaseThird of patientsBetter Informed TreatmentManagement of patientsOAC typeAntiplatelet therapyDiabetes mellitusFemoral accessContemporary cohortOutcomes RegistryKidney diseaseMyocardial infarction
2019
Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation
Freeman JV, Shrader P, Pieper KS, Allen LA, Chan PS, Fonarow GC, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel JA, Singer DE, Go AS, Hylek EM, Steinberg BA, Peterson ED, Piccini JP. Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. Circulation Arrhythmia And Electrophysiology 2019, 12: e007612. PMID: 31830822, DOI: 10.1161/circep.119.007612.Peer-Reviewed Original ResearchConceptsAF catheter ablationOral anticoagulationRisk of strokeAF ablationCatheter ablationAntiarrhythmic medicationsDe novo AF ablationDiscontinuation of OACPropensity score-matched cohortAtrial fibrillation catheter ablationAF ablation patientsAnti-arrhythmic medicationsAtrial Fibrillation RegistryStroke prevention therapyBetter Informed TreatmentCohort of patientsPatterns of treatmentProportional hazards regressionUS national registryAnticoagulation useCause deathMajor bleedingSystemic embolismCardiovascular deathCause hospitalization
2018
Atrial Fibrillation Thermographic and Endoscopic Monitoring of Patients: Safety Algorithm for the Esophagus
Hummel JP, Kadado AJ, Baker M, Gehi AK, Mounsey JP, Sadaf MI, Enriquez AD, Freeman JV, Akar JG. Atrial Fibrillation Thermographic and Endoscopic Monitoring of Patients: Safety Algorithm for the Esophagus. Circulation Arrhythmia And Electrophysiology 2018, 11: e006814. PMID: 30562101, DOI: 10.1161/circep.118.006814.Peer-Reviewed Original ResearchB-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation
Inohara T, Kim S, Pieper K, Blanco RG, Allen LA, Fonarow GC, Gersh BJ, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Mahaffey KW, Singer DE, Freeman JV, Steinberg BA, Peterson ED, Piccini JP. B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. Heart 2018, 105: 370. PMID: 30228248, DOI: 10.1136/heartjnl-2018-313642.Peer-Reviewed Original ResearchConceptsB-type natriuretic peptideAtrial fibrillationAF progressionBNP levelsMajor bleedingBNP valuesNatriuretic peptideDisease progressionAtrial Fibrillation II registryBiomarker-based risk stratificationElevated BNP valuesBetter Informed TreatmentPersistent atrial fibrillationCox frailty modelCardiovascular outcomesComposite outcomeBNP concentrationsNeurological eventsClinical outcomesOutcomes RegistryRisk stratificationPatient outcomesInformed TreatmentPatientsBleedingPrognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation
O'Brien EC, Holmes DN, Thomas LE, Fonarow GC, Allen LA, Gersh BJ, Kowey PR, Singer DE, Ezekowitz MD, Naccarelli GV, Ansell JE, Chan PS, Mahaffey KW, Go AS, Freeman JV, Reiffel JA, Peterson ED, Piccini JP, Hylek EM. Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. Circulation 2018, 138: 889-897. PMID: 29678813, DOI: 10.1161/circulationaha.117.031354.Peer-Reviewed Original ResearchConceptsStroke/systemic embolismMajor bleedingOral anticoagulantsAtrial fibrillationMinor bleeding eventsSubset of patientsVASc risk scorePooled logistic regressionYears of ageBleeding eventsEligible followOAC discontinuationOAC therapyOutpatient registrySystemic embolismAnticoagulated patientsMinor bleedingMedian ageTreatment satisfactionPrognostic significanceNuisance bleedingMedical recordsORBIT-AFIncidence ratePatient visitsStroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA2DS2‐VASc Scores: Findings From the ORBIT‐AF I and II Registries
Jackson L, Kim S, Fonarow GC, Freeman JV, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Singer D, Thomas L, Blanco R, Peterson ED, Piccini J, Patients and Investigators T. Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA2DS2‐VASc Scores: Findings From the ORBIT‐AF I and II Registries. Journal Of The American Heart Association 2018, 7: e008764. PMID: 30369317, PMCID: PMC6201408, DOI: 10.1161/jaha.118.008764.Peer-Reviewed Original ResearchConceptsOral anticoagulationAtrial fibrillationTreatment strategiesCardiology/American Heart Association guidelinesStroke/transient ischemic attackLow CHA2DS2-VASc scoreAmerican Heart Association guidelinesCHA2DS2-VASc scoreThromboembolic event rateTransient ischemic attackHeart Association guidelinesCurrent American CollegePatterns of treatmentIschemic attackVASc scoreCause mortalityStroke riskTreatment patternsAbsolute riskAssociation guidelinesStroke rateVAScAmerican CollegeLower riskPatientsCharacteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation
Durheim MT, Holmes DN, Blanco RG, Allen LA, Chan PS, Freeman JV, Fonarow GC, Go AS, Hylek EM, Mahaffey KW, Pokorney SD, Reiffel JA, Singer DE, Peterson ED, Piccini JP. Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart 2018, 104: 1850. PMID: 29875139, DOI: 10.1136/heartjnl-2017-312735.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnti-Arrhythmia AgentsAnticoagulantsAtrial FibrillationComorbidityFemaleHealth StatusHeart Conduction SystemHemorrhageHospitalizationHumansLungMalePrevalencePulmonary Disease, Chronic ObstructiveQuality of LifeRegistriesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseAtrial fibrillationSymptom burdenHeart failurePulmonary diseaseHigh riskDiagnosis of COPDNew-onset heart failureTreatment of AFBeta-blocker useCardiovascular risk factorsMajor bleeding eventsHigh symptom burdenBetter Informed TreatmentCoronary artery diseaseOutcomes of adultsQuality of lifeBleeding eventsDigoxin useBlocker useCause mortalityProspective registryReversible causesCardiovascular mortalityUnderuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review
Hsu JC, Freeman JV. Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review. Clinical Pharmacology & Therapeutics 2018, 104: 301-310. PMID: 29328506, DOI: 10.1002/cpt.1024.Peer-Reviewed Original ResearchConceptsAtrial fibrillationStroke preventionVitamin K antagonistsDirect oral anticoagulantsNonvalvular AF patientsOral anticoagulant therapyRisk of strokeSpecial patient populationsSerious clinical problemOAC therapyK antagonistsOral anticoagulantsAnticoagulant therapyAF patientsPatient populationLeading causeClinical problemPatientsSignificant deleterious impactPreventionFibrillationTherapyContemporary reviewStrokeUnderuse
2015
Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT‐AF Registry
Jackson LR, Kim SH, Piccini JP, Gersh BJ, Naccarelli GV, Reiffel JA, Freeman J, Thomas L, Chang P, Fonarow GC, Go AS, Mahaffey KW, Peterson ED, Kowey PR. Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT‐AF Registry. Clinical Cardiology 2015, 39: 119-125. PMID: 26720750, PMCID: PMC4784163, DOI: 10.1002/clc.22504.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAtrial FibrillationChi-Square DistributionComorbidityDisease ProgressionFemaleHumansLogistic ModelsMaleOdds RatioProportional Hazards ModelsProspective StudiesQuality of LifeRegistriesRisk AssessmentRisk FactorsSeverity of Illness IndexSick Sinus SyndromeTime FactorsTreatment OutcomeUnited StatesConceptsSinus node dysfunctionPermanent atrial fibrillationHigh symptom burdenAtrial fibrillationRisk-adjusted outcomesSymptom burdenTreatment patternsComorbid medical illnessesOutcomes of patientsAdverse cardiovascular outcomesParoxysmal atrial fibrillationPersistent atrial fibrillationORBIT-AF registryAF management strategyLogistic regression analysisCardiovascular outcomesComorbid illnessesAtrial tachyarrhythmiasMedical illnessHigh riskSevere symptomsPatientsDysfunctionOutcomesRegression analysis
2014
Digoxin and Risk of Death in Adults With Atrial Fibrillation
Freeman JV, Reynolds K, Fang M, Udaltsova N, Steimle A, Pomernacki NK, Borowsky LH, Harrison TN, Singer DE, Go AS. Digoxin and Risk of Death in Adults With Atrial Fibrillation. Circulation Arrhythmia And Electrophysiology 2014, 8: 49-58. PMID: 25414270, PMCID: PMC4334705, DOI: 10.1161/circep.114.002292.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAnti-Arrhythmia AgentsAtrial FibrillationCaliforniaChi-Square DistributionDigoxinFemaleHospitalizationHumansKaplan-Meier EstimateMaleMiddle AgedPatient SelectionPropensity ScoreProportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsTreatment OutcomeConceptsRisk of deathIncident atrial fibrillationAtrial fibrillationDigoxin useHigh riskHeart failureIndependent associationPropensity score-matched adultsKaiser Permanente NorthernPrevious heart failureRetrospective cohort studyResearch Network StudySubgroups of ageCohort studyCox regressionAdverse outcomesRisk factorsHospitalizationFibrillationDigoxinDeathLimited dataAdultsRiskHigh rate
2009
Should the exercise ECG be used to screen for sudden cardiac death?
Freeman J, Ashley EA, Froelicher V. Should the exercise ECG be used to screen for sudden cardiac death? European Heart Journal 2009, 30: 528-529. PMID: 19201762, DOI: 10.1093/eurheartj/ehp029.Peer-Reviewed Original Research